EPCAM and cancer: This reduction correlated with increased expression of stem cell markers, such as PROM1, CK19, DLK1, SALL4, and EPCAM (Fig 3C), suggesting that low SLC2A2 levels may promote cancer stem cell traits, malignancy, and therapeutic resistance.